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Projecting the COPD population 
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2011 to 2030
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Sarah Wild1, Colin R. Simpson1, Maureen Rutten-van Mölken2 & Aziz Sheikh1
We aimed to estimate the prevalence, healthcare costs and number of deaths among people with 
chronic obstructive pulmonary disease (COPD) in England and Scotland 2011–2030. We adapted the 
Dutch COPD Model by using English and Scottish demographic, COPD incidence, COPD prevalence, 
smoking prevalence and mortality data to make projections. In England, the prevalence of COPD was 
estimated to be 1.79% (95% uncertainty interval 1.77–1.81) in 2011, increasing to 2.19% (1.85–2.33) by 
2030. In Scotland, prevalence was 2.03% (1.96–2.10) in 2011 increasing to 2.20% (1.98–2.40) in 2030. 
These increases were driven by more women developing COPD. Annual direct healthcare costs of COPD 
in England were estimated to increase from £1.50 billon (1.18–2.50) in 2011 to £2.32 (1.85–3.08) billion 
in 2030. In Scotland, costs increased from £159 million (128–268) in 2011 to £207 (165–274) million 
in 2030. The deaths in England were estimated to increase from 99,200 (92,500–128,500) in 2011, to 
129,400 (126,400–133,400) by 2030. In Scotland, in 2011 there were 9,700 (9,000–12,300) deaths and 
13,900 (13,400–14,500) deaths in 2030. The number of people with COPD will increase substantially 
over the coming years in England and Scotland, particularly in females. Services need to adapt to this 
increasing demand.
Chronic obstructive pulmonary disease (COPD) poses a substantial healthcare burden on many countries. The 
most recent figures from the Global Burden of Disease Study 20101 show that it is now the third leading global 
cause of death2.
Projecting the future numbers of people who will suffer chronic disease is essential for governments to plan 
their healthcare budgets and resource deployment.
In order to inform modelling for England and Scotland, we undertook a systematic review to identify and 
evaluate models that estimate the prevalence and COPD burden3,4. We identified 22 such models which used a 
range of techniques. Three related models scored highly for quality; they were developed by Erasmus University, 
Rotterdam, and RIVM, Bilthoven, the Netherlands, and cross validated with other models5–8. Following contact 
with the authors we agreed that we could use their most up-to-date “Dutch COPD Model” with English and 
Scottish data to produce projections for the prevalence, costs and number of deaths from COPD over the period 
2011–2030.
Methods
The Dutch COPD Model general description. The Dutch COPD Model was developed by The Institute 
for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands and The National Institute 
for Public Health and the Environment, Bilthoven, The Netherlands. It has been described in detail in several 
publications6,7,9,10. Figure 1 shows the structure of the Dutch COPD Model. Figure 1 should be read from left to 
right and top to bottom. The model is a multi-state model describing the following states: no COPD, mild, mod-
erate, severe, very severe and death. The model follows COPD patients over the course of disease from incidence 
until death. In the model incidence, prevalence, mortality, progression and health care costs of COPD are speci-
fied by 2007 Global initiative for Obstructive Lung Disease (GOLD) severity stage11.
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The model follows a cohort starting out with no COPD but with specific age, sex and smoking rates, then, year 
on year, members of each cohort develop COPD. For each cohort the prevalence and incidence of COPD, within 
this population, is calculated. Each year a new birth cohort is added to the non-COPD population and existing 
cohorts age one year. The annual incidence of new cases of COPD is modelled taking into account the start, stop 
and restart rates of smoking within the general population. Prevalent COPD cases are modelled to progress to 
worse severity stages over time and changes in smoking status can occur. Each COPD severity state is associated 
with a certain risk to die of COPD or another cause. In addition, patients in each COPD severity state have a risk 
of experiencing exacerbations. This risk increases with increasing COPD severity. Healthcare costs are calculated 
as the costs for maintenance treatment specified by severity state and the costs of treating exacerbations. Main 
outcomes of the model are number of COPD patients, number of deaths, and COPD-related treatment costs 
over time. Extensive details about the model can be found in previous publications about the model and in the 
Supplement. The adapted input parameters are described below.
Starting point. The starting point of the current model simulation was the English or Scottish population in 
the baseline year of 2011 in terms of demographics (age and sex), smoking status (smokers, former smokers and 
never- smokers) and the incidence and prevalence of COPD by age and sex in one year age classes.
Use of English and Scottish input data-ethics and governance issues. English and Scottish input 
data were required for a variety of inputs (Table S1 in the Supplement). Data sources were identified through 
discussion between the teams in Edinburgh and Rotterdam. A National Health Service (NHS) Research Ethics 
Committee approval waiver was granted for use of the English and Scottish data, on the understanding that the 
data were anonymised. Permission to use Clinical Practice Research Datalink (CPRD) data was granted from the 
Independent Scientific Advisory Committee (ISAC) of CPRD, which oversees all applications to CPRD (Approval 
10-084RA). An approval waiver for analysis required for the Lothian COPD Cohort was granted by the Privacy 
Advisory Committee (PAC) at Information Services Division (ISD). Caldicott Guardian permission for aggre-
gated data from the Lothian COPD Cohort to be used outside the UK was also granted. The Supplement contains 
tables of input data and details of calculations based on the data.
Demographic details for England and Scotland. Country specific demographic data were obtained 
from the Office for National Statistics for England (Table S2 in the Supplement) and the General Register’s Office 
for Scotland (Table S3).
The incidence of COPD. Incidence of COPD under 35 years of age was negligible. In those aged over 35, 
the incidence of COPD in England was calculated using the CPRD dataset. CPRD is a large UK-based dataset of 
routinely collected health data, funded by the National Institute for Health Research (NIHR) and the Medicines 
and Healthcare Products Regulatory Agency (MHRA). CPRD extracts data from electronic medical records in 
primary care. We used the CPRD dataset that was used to develop a prognostic model for COPD12. With per-
mission from CPRD, the analysis of Kotz et al.12, was extended to provide incidence and prevalence estimates for 
Figure 1. The Dutch COPD Model (reproduced with permission from Hoogendoorn, M., Rutten-Van 
Molken, M. P. M. H., Hoogenveen, R., Maiwenn, J. & Feenstra, T. L. Developing and applying a stochastic 
dynamic population model for chronic obstructive pulmonary disease. Value Health. 14, 1039–1047. Epub 
2011 Sep 1022). (2011). 
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COPD in primary care (further details in the Supplement). The dataset contained 38,606 patients coded as COPD 
(Tables S4 and S5 in the Supplement). We used data from only the English patients in this database to calculate 
the incidence for England.
For Scotland, the incidence was calculated from the Lothian COPD Cohort Database. This database consists 
of all new diagnoses of COPD in the region of Lothian between 2000 and 2008. This incidence was adjusted by 
Scottish Index of Multiple Deprivation (SIMD) to apply to the whole of Scotland. (Table S6).
The incidence of COPD in each age and gender class was distributed over the three smoking classes using 
the number of smokers in each class and the relative risks of smokers and former smokers of having COPD. The 
frequency distribution of the FEV1% predicted among the incident cases was estimated by the model and defined 
as the distribution that, given disease progression and mortality, would not change the FEV1 predicted among the 
prevalent cases in the first year of the model. Therefore 40% of newly diagnosed COPD patients had mild COPD 
55% had moderate, 4% had severe and 0.1% had very severe.
The prevalence of COPD. CPRD was used to estimate the prevalence in one year age and sex groups for 
English patients (Table S7).
All COPD patients should be reviewed at least once a year under the terms of the Quality and Outcomes 
Framework (QOF) of the GP General Medical Services Contract in both England and Scotland13. Therefore, a 
reasonable proxy for the prevalence was the number of people consulting a general practitioner (GP) or nurse at 
least once during a 15 month period for COPD divided by the mid-point practice population.
For Scotland, this number was obtained from the Practice Team Information (PTI) Database, which com-
prises of a sample of approximately 6% of Scottish GPs who download their data to Information Services Division 
(ISD), a special health board in Scotland. The codes selected were the codes used to allocate QOF payments to 
GPs (Table S8). To ensure that this prevalence was accurate the SIMD was used to correct the PTI data to the 
whole of Scotland according to deprivation quintiles (Table S9).
The prevalence of COPD in each age and gender class is distributed over the three smoking classes using the 
number of smokers in each smoking class and the relative risks of smokers and former smokers to have COPD. It 
is assumed that the relative risks of smokers and former smokers to get COPD is equal to the relative risk of hav-
ing COPD. The prevalence of COPD in each age, sex and smoking class is further distributed over the four GOLD 
stages. This was inputted from a frequency distribution of FEV1% predicted over all COPD classes obtained 
from Dutch GP data. Based on a normal distribution with a mean FEV1% predicted of 68.3% (SD 19.9%) it was 
estimated that 27% had mild COPD 55% had moderate COPD, 15% had severe COPD and 3% had very severe 
COPD. Frequency distributions of English and Scottish severity were not available at the time of the analysis 
however, subsequently, we have confirmed that the severity distribution in a representative English dataset was 
mean FEV1% predicted of 68.9% (SD 17.3%) (Health Survey for England 2010)14 and so very similar to the Dutch 
distribution. The severity distribution of the Scottish data was later confirmed as mean FEV1% predicted 59.0% 
(SD 18.8%) (Lothian COPD Cohort).
Smoking. Each year transitions between smoking stages occur. Non–smoking patients could start smoking, 
smoking patients could stop smoking and former smoking patients had a certain probability to restart smoking.
The General Lifestyle Survey for England 201115 provided estimated proportions of current and former smokers 
for England in adults. For under 16 s, data were retrieved from the Health Survey for England 2010 (Table S10)14.
The proportion of the Scottish adult population who were smokers, former smokers and never smokers was 
obtained from the Scottish Health Survey 201116. Data for under 16 s were extracted from the Scottish Schools 
Adolescent Lifestyle and Substance Use Survey 2010 (Table S11)17.
Additional smoking data: Start, stop and restart probabilities for smoking. Models for England 
and Scotland both used the following data:
•	 Numbers and ages of starting smoking from the Avon Longitudinal Study of Parents and Children (ALSPAC), 
a cohort study of over 14000 mothers, partners and children who were enrolled during their pregnancies in 
1991/2. Approximately 30% of the parental male and female cohort were smokers18. The whole cohort had 
been asked whether they were smokers and at what age they had started smoking. We used this to generate an 
age related probability of starting smoking within the cohort. We directly transferred this probability to the 
populations of Scotland and England.
•	 For stopping smoking, we used the proportion of the total population, by age and sex, who were smokers who 
had successfully stopped for over a year from the Smoking Toolkit Survey (Table S12)19.
•	 Restarting smoking probabilities were used from the original Dutch Model as no equivalent survey was iden-
tified for England or Scotland. These data came from an annual Dutch Survey of smokers20.
Relative risks of smokers and non-smokers. The age- and sex-specific relative risks of smokers and 
non-smokers to develop COPD were left the same as in the original Dutch Model. This was because the original 
data came from the United States Surgeon General’s report and such risks were assessed as being consistent across 
populations, being more to do with the biology of COPD than with epidemiology10,21,22.
Disease progression. In those with established COPD there is a probability to progress to the next level 
of COPD severity. This disease progression was modelled as an annual decline in FEV1% predicted depending 
on age, sex, smoking status and FEV1% predicted. This annual decline is based on a random effects analysis of 
5,000 patients in the Lung Health Study23. Details of the calculation of lung function decline are published in the 
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Appendix to the 2005 Hoogendoorn et al. European Respiratory Journal article7. The values found were used 
in two ways: firstly, to describe the change of the FEV1 distribution within a particular COPD state, and subse-
quently, to calculate the transition rates between COPD states. This first use of the lung function decline values 
is the unique feature of our model. Exacerbations accelerate lung function decline. Disease progression was not 
adapted for the current study.
Exacerbations. Each severity stage is associated with a risk for a moderate or a severe exacerbation as deter-
mined by previous work24. A moderate exacerbation was defined as necessitating a prescription of antibiotics 
and steroids. A severe exacerbation was defined as a hospital admission10. Exacerbations accelerate lung function 
decline and there was also an exacerbation related mortality which was calculated from a previous meta-analysis 
by the Dutch team25. Exacerbation probabilities in the model were based on a systematic review and meta-analysis 
of about 20 studies and were not adapted for the current study24.
Costs. The direct healthcare costs of caring for people with COPD were divided into maintenance costs for 
the ongoing care of people with COPD and the additional costs for moderate or severe exacerbations. Costs 
associated with maintenance treatment for COPD were specified by GOLD COPD stage during the modelling. 
They were obtained from a micro-costing for a cost utility analysis of indacaterol, which gave list prices and an 
estimate of average annual usage statistics that came from a large COPD patient database or from expert opinion 
via a Delphi process26. Multiplying cost by usage generated an average total cost per severity stage (Table S13). 
Maintenance costs were calculated by multiplying the annual number of patients alive with the COPD-related 
maintenance costs specified by COPD severity stage.
Costs related to exacerbations came from a tiotropium study’s Delphi panel’s estimates for exacerbations in 
England and Scotland27. The authors calculated that the cost of a moderate exacerbation was £118 and the cost of 
a severe exacerbation, was £3,726 in England and £3,329 in Scotland. Exacerbation-related costs were calculated 
as the model projected numbers of moderate and severe exacerbations each year multiplied by the cost per exac-
erbation. Cost per patient and cost per exacerbation were assumed constant over time.
Mortality. In the model all-cause mortality among COPD patients was divided into “excess mortal-
ity” and “mortality from other causes”, where “excess mortality” was defined as the difference in mortality 
between COPD patients and the general population which includes the increased risk of dying from other 
Figure 2. Projected number of people with COPD in England and Scotland. 
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smoking-related diseases. COPD excess mortality and mortality in the general population were used to calculate 
the COPD-attributable mortality in the model9.
The modelling parameter of “excess mortality” was calculated as detailed in the Supplement. The model esti-
mated the annual number of deaths from all causes among the COPD population.
Making projections. A collaboration between the authors of the Dutch COPD Model and The University of 
Edinburgh enabled the Dutch model to be run with input data from England and Scotland from the year 2011. 
Projections for the number of COPD patients specified by gender, age, smoking status and COPD disease severity 
and the number of exacerbations were run for 20 years to 2030. The projections were an extrapolation of current 
observed trends in smoking behaviour and disease progression assuming they remain constant over time.
Sensitivity analyses. A number of one-way sensitivity analyses were performed, these demonstrate the 
sensitivity of the model to each parameter when altered one at a time. For the first three sensitivity analyses, we 
explored the impact of a 10% decrease and a 10% increase in incidence, prevalence and lung function decline. In 
the fourth sensitivity analysis, the severity distribution of the prevalence at baseline was shifted towards milder 
COPD and towards more severe COPD by changing the mean FEV1% predicted in the population by 10% in 
each direction. The fifth sensitivity analysis used excess mortality from another European modelling study, 
DYNAMO-HIA28,29. Next, an increase in the smoking cessation rate to 10% at all ages was modelled to see what 
effect an optimal public health policy change might have.
Figure 3. Projected direct healthcare costs of COPD. 
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Additional probabilistic sensitivity analysis. Probabilistic sensitivity analysis was undertaken to 
estimate the effects of uncertainty around the different input parameters on the outcomes. See Supplementary 
information.
Results
Population and prevalence with COPD. England. For England, we estimated that the number of people 
with COPD would increase from 0.95 million (95% uncertainty interval 0.94–0.96 million) in 2011 to 1.3 million 
(1.1–1.4 million) in 2030 (an increase of 39%) (Fig. 2). The prevalence of diagnosed COPD among males was 
estimated as 1.8% (1.8–1.9) in 2011, increasing to 2.0% (1.7–2.1) in 2030 and 1.8% (1.7–1.8) in females in 2011 
increasing to 2.4% (2.0–2.6) in females by 2030.
Scotland. For Scotland, we estimated that there would be 0.10 million (0.10–0.11 million) people with diagnosed 
COPD in 2011, increasing to 0.12 million (0.11–0.13 million) (an increase of 17%) in 2030 (see Fig. 2). The preva-
lence among males was estimated as 1.9% (1.8–1.9) in 2011, staying at 1.9% (1.7–2.2) in 2030 and 2.2% (2.1–2.3) 
in females in 2011, increasing to 2.5% (2.1–2.7) by 2030.
Direct healthcare costs of COPD. England. The total annual direct healthcare costs for people with 
COPD including moderate and severe exacerbation costs and maintenance costs were projected to increase from 
£1.50 billon (1.18–2.50) in 2011 to £2.32 (1.85–3.08) billion by 2030 (Fig. 3).
Scotland. Total annual direct healthcare costs for caring for people with COPD were projected to increase from 
£159 million (128–268) in 2011 to £207 (165–274) million by 2030 (Fig. 3).
Figure 4. Projected number of deaths among people with COPD from all causes. 
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Deaths from COPD. England. The number of deaths among people with COPD was estimated to increase 
from 99,200 (92,500–128,500) to 129,400 (126,400–133,400) in 2030 (Fig. 4).
Scotland. There were estimated to be 9,700 (9,000–12,300) deaths in 2011 and 13,900 (13,400–14,500) deaths 
from all causes among people with COPD in 2030 (Fig. 4).
Sensitivity analyses. The model projections were most sensitive to changes in the excess mortality of 
COPD. It can be seen that the sensitivity of the projection of prevalence in 2030 to one way changes in differ-
ent parameters had a similar pattern for both countries from the tornado diagrams for England and Scotland 
(Fig. 5)30. It should be noted that using the DYNAMO-HIA excess mortality resulted in higher mortality rates 
and therefore the increase in the COPD population over time was lower compared to the base case analysis in this 
sensitivity analysis29.
Comparison between countries. The percentage increase projected among English females with COPD 
is 54% between 2011 and 2030, among Scottish females this increase is 22%. Among English males there will be 
an estimated increase of 24%, in Scotland among males this increase is 11%. The reasons for these differences 
Figure 5. Tornado diagrams of sensitivity analysis projections of prevalence for 2030 as compared to base 
case (%). 
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are down to differences in the modelling parameter of excess mortality calculated for each group, (Fig. 6). The 
excess mortality varies because English females have the longest life expectancy and the lowest rate of smok-
ing and Scottish males have the shortest life expectancy and the highest rate of smoking, (Fig. 7). Therefore 
English females live longest, giving time for lung function decline to become apparent as COPD even if they are 
ex-smokers. Scottish males have comparatively more smokers and therefore have a high associated mortality, this 
means that the smokers do not live long enough to contribute greatly to the percentage increase in COPD.
Discussion
Principal findings. Our dynamic population models for England and Scotland projected substantial year-
on-year increases in the numbers of people with COPD over the period 2011–2030. These projections are similar 
to the Netherlands showing an increase, especially among older female patients7.
As a result of the increase in the prevalence, the models projected an increase in direct healthcare costs for 
the overall COPD population, and also an increase in the number of deaths from all causes among people with 
COPD.
Strengths and limitations. The strengths of this approach include our decision, informed by a formal sys-
tematic review, to use the Dutch COPD Model5,7 with data which had been collected for routine clinical practice; 
Figure 6. Age related excess mortality due to COPD per 1000 population. 
Figure 7. Percentage prevalence of smoking by age. 
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the data therefore had high validity. The Dutch COPD Model has been cross-validated with other models for 
hypothetical treatment scenarios8.
A limitation is that models structured by the GOLD severity stages in COPD have been criticised for having 
too narrow a view of the elements which predict COPD progression as recent arguments have been made that 
COPD severity is a complex mix of co-morbidity, susceptibility to exacerbations and symptoms31. The GOLD 
2013 guidelines were updated to reflect this. Yet it has since been shown that although the 2013 GOLD classifi-
cation is better than the 2007 GOLD classification at predicting exacerbations it is worse at predicting mortality 
and lung function decline32. Clinical predictive models do exist, but these are based on a few trials and so model 
individuals’ progression through micro-simulation31. These are more relevant for the evaluation of treatment 
options than for making projections. A further limitation is that the model did not take into account any change 
in diagnosis rates of COPD. Several studies have proposed that there is substantial under-diagnosis of COPD in 
England33. If this is correct, the current estimates of the COPD population are likely to be conservative. It should 
also be remembered that the projections are an extrapolation of currently observed trends in smoking behaviour. 
Stop smoking rates were obtained from the Smoking Toolkit Survey19 and defined as the proportion of the total 
population, by age and sex, who were smokers who had successfully stopped for over a year. Using this definition 
also means that the current projections of prevalence and costs are probably conservative estimates.
The model did not consider any changes in the cost of treatment. As a result the current projections of 
COPD-related healthcare costs are also likely to be conservative as in general healthcare costs increase over time.
Implications for policy and research. In due course, it will be possible to externally validate these projec-
tions with the actual number of people with COPD. Meanwhile, these projections should be considered for plan-
ning for the increased numbers, costs and care needs of people with COPD. This will be in the context of England 
and Scotland facing an increasing elderly and frail population with high rates of multi-morbidity34.
Internationally, similar modelling using local data sources should be considered for projection of the rates and 
cost of COPD.
We acknowledge that policymakers also need cost-effectiveness, cost-utility and cost-benefit studies to help 
them allocate resources.
A general point can also be made about the challenge of representing a complex disease in the form of a 
state-transition Markov Model. COPD is recognised to result from the interplay of host factors, co-morbidities 
and the external environment. Modelling is thus an over simplification. More research and better data are needed 
to advance the science of epidemiological modelling.
Conclusions
The COPD populations in England and Scotland are projected to increase substantially over the coming years 
to 2030. There will also be increases in the healthcare costs of COPD patients and the number of deaths among 
COPD patients. These increases need to be taken into account by policymakers when planning healthcare deploy-
ment and resource allocation for the future.
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